'Clinical care. At-home diagnostics. One app.' 'A GLP-1 program built to maximize adherence and bend your healthcare cost curve.' Claims >90% program adherence, 14.2-month average duration, 98% reduction in prediabetes risk among flagged members. 'Most GLP-1 programs simply prescribe medication' - eMed leads with adherence monitoring and population-health intelligence.
Employers and benefits buyers managing GLP-1 coverage cost; members are employees, not direct consumers.
Employer-contracted; no consumer pricing published. Site claims direct pricing on FDA-approved medications with no PBM markups or rebate inflation.
Own clinical intake and monitoring platform with at-home diagnostics (HbA1c, lipids, nutritional-deficiency screening) and 24/7 clinical support.
'Direct pricing on FDA-approved medications' claimed; dispensing pharmacy not named on reviewed pages.
Google: count header displayed '0 ads' while 6 cards from verified advertiser eMed Population Health, Inc. rendered (20 Oct 2026; known display inconsistency). Meta keyword 'emed.com' ~36 results. LinkedIn: no attributable ads among 5,332 fuzzy matches. See dated channel evidence.
Not established in this pass.
CEO Linda Yaccarino (former X CEO), per Reuters 5 Aug 2025. Founders not confirmed in this pass.
Not stated on pages reviewed.
Not assessed in this pass.